Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
| ▸ | F3 | P13726 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 2/20 | 0.36 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.33 |
| ▸ | BCKDK | O14874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL209055 | 0.83 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9AMAPTKDM4E | |
| SCHEMBL206753 | 0.75 | GFER (0.44) | SMN1; SMN2NPC1RAB9AMAPTKDM4E | |
| SCHEMBL212513 | 0.75 | MAPT (0.44) | NPC1RAB9AMAPTKDM4EALDH1A1 | |
| SCHEMBL4718799 | 0.75 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1RAB9AMAPTKDM4E | |
| SCHEMBL6601753 | 0.75 | HTT (0.44) | MAPTKDM4EALDH1A1GAAHTT | |
| SCHEMBL20542591 | 0.74 | — | — | |
| SCHEMBL211098 | 0.74 | MAPK13 (0.36) | DYRK1A | |
| SCHEMBL5535847 | 0.72 | PIK3CA (0.50) | ALDH1A1GAADYRK1APIK3CG | |
| SCHEMBL11224145 | 0.71 | APP (0.42) | KDM4EALDH1A1GAADYRK1AAPP | |
| SCHEMBL11122399 | 0.71 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667644-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-06 | — | — | US | claimed |
| US-RE48841-E1 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-07 | — | — | US | claimed |
| US-20210347781-A1 | Disubstituted Octahydropyrrolo[3,4-c]Pyrroles As Orexin Receptor Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-11 | — | — | US | claimed |
| US-20210292281-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | REATA PHARMACEUTICALS, INC. (US) | 2021-09-23 | — | — | US | claimed |
| US-20210147435-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2021-05-20 | — | — | US | claimed |
| CN-112654610-A | Pyrazole and imidazole compounds for inhibiting IL-17 and ROR gamma | 里亚塔医药公司 | 2021-04-13 | — | — | CN | claimed |
| EP-3665156-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2020-06-17 | — | — | EP | claimed |
| CN-111094233-A | Compounds, compositions and methods | 戴纳立制药公司 | 2020-05-01 | — | — | CN | claimed |
| WO-2019032743-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2019-02-14 | — | — | WO | claimed |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-18 | — | — | US | claimed |
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | UBE INDUSTRIES, LTD. (JP) | 2003-11-20 | — | — | US | claimed |
| EP-1100797-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER LTD (GB) | 2003-02-26 | — | — | EP | claimed |
| EP-1254897-A1 | TRICYCLIC COMPOUNDS | Ube Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | claimed |
| US-6372736-B1 | ENZYME INHIBITORS | PFIZER INC | 2002-04-16 | — | — | US | claimed |
| EP-1100797-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | Pfizer Limited (GB) | 2001-05-23 | — | — | EP | claimed |
| WO-2000005232-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER LIMITED (GB) | 2000-02-03 | — | — | WO | claimed |
| US-5639282-A | MONOAZO DYE CONTAINING CARBOXYLIC ESTER; GOOD FASTNESS, ALKALI STABILITY | DYSTAR JAPAN, LTD. (JP) | 1997-06-17 | — | — | US | claimed |
| US-4994563-A | Dyeing, printing cellulose, silk, wool, synthetic polyamides; colorfastness | CIBA-GEIGY CORPORATION (US) | 1991-02-19 | — | — | US | claimed |
| EP-0349486-A2 | Azo dyes, their preparation and their use | CIBA-GEIGY AG (CH) | 1990-01-03 | — | — | EP | claimed |
| US-4022762-A | Water-soluble acid azo dyestuff containing a N-(p-sulphophenoxyalkyl)-N-alkyl amino group | PRODUITS CHIMIQUES UGINE KUHLMANN (FR) | 1977-05-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | FASN, PLIN1, FABP1 | SMN1; SMN2 2272/4885NPC1 969/4885RAB9A 1530/4885 |
| US-20210347781-A1 | Disubstituted Octahydropyrrolo[3,4-c]Pyrroles As Orexin Receptor Modulators | HCRTR2, HCRTR1, OXTR | SMN1; SMN2 3009/4885NPC1 1202/4885RAB9A 2680/4885 |
| US-20210292281-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | RORC, RORB, RORA | SMN1; SMN2 4488/4885NPC1 3137/4885RAB9A 1311/4885 |
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | CYSLTR2, CYSLTR1, LTC4S | SMN1; SMN2 3963/4885NPC1 2305/4885RAB9A 4766/4885 |
| US-11667644-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | SMN1; SMN2 3009/4885NPC1 1202/4885RAB9A 2680/4885 |
| US-20210147435-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | EIF4EBP1, EIF4B, EIF4E | SMN1; SMN2 1096/4885NPC1 995/4885RAB9A 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.